Melt Pharmaceuticals, a Nashville, TN-based scientific‑stage pharmaceutical firm, raised $24M in Sequence B Most well-liked Inventory financing.
The corporate intends to make use of the funds to help the additional growth of MELT-300, together with the MELT-300 Section 3 program.
Led by CEO Dr. Larry Dillaha, Soften Prescribed drugs is a clinical-stage pharmaceutical firm targeted on growing proprietary non-opioid, non-IV, sedation, and analgesia therapeutics for human medical procedures within the hospital, outpatient, and in-office settings. It intends to hunt regulatory approval by way of the FDA’s 505(b)(2) regulatory pathway for its proprietary, patented small-molecule product candidates, the place potential. Its core mental property is the topic of a number of granted patents in North America, Europe, Asia, and the Center East. The corporate is a former subsidiary of Harrow, Inc. (Nasdaq: HROW) and was carved out as a individually managed enterprise in 2019.
Commenting on the information, Dr. Larry Dillaha mentioned: “Soften is looking for to drive a paradigm shift in procedural sedation, fulfilling an unmet want to offer a needle- and opioid-free different for procedural sedation, particularly in cataract surgical procedures, that are estimated at over 4.5 million procedures within the U.S. As we proceed to develop our patented applied sciences, we consider we will additionally impression the greater than 100 million short-duration medical procedures nationwide.”
FinSMEs
02/04/2024
